title: Mesoporous silica nanoparticles in medicine--recent advances.
abstract: MSNs have attracted increasing interest as drug carriers due to promising in vivo results in small-animal disease models, especially related to cancer therapy. In most cases small hydrophobic drugs have been used, but recent in vitro studies demonstrate that MSNs are highly interesting for gene delivery applications. This review covers recent advances related to the therapeutic use of mesoporous silica nanoparticles (MSNs) administered intravenously, intraperitoneally or locally. We also cover the use of MSNs in alternative modes of therapy such as photodynamic therapy and multidrug therapy. We further discuss the current understanding about the biodistribution and safety of MSNs. Finally, we critically discuss burning questions especially related to experimental design of in vivo studies in order to enable a fast transition to clinical trials of this promising drug delivery platform.
authors.affiliation: Turku Centre for Biotechnology, University of Turku and Åbo Akademi University, P.O. Box 123, FI-20521, Turku, Finland.
authors.forename: Veronika
authors.initials: V
authors.lastname: Mamaeva
authors.forename: Cecilia
authors.initials: C
authors.lastname: Sahlgren
authors.forename: Mika
authors.initials: M
authors.lastname: Lindén
mesh_terms: D000818:Animals; D016503:Drug Delivery Systems / Q000379:methods*; D006801:Humans; D053758:Nanoparticles / Q000008:administration & dosage / Q000737:chemistry*; D009369:Neoplasms / Q000737:chemistry / Q000188:drug therapy / Q000378:metabolism; D010316:Particle Size; D010789:Phototherapy / Q000379:methods; D016062:Porosity / Q000187:drug effects; D012822:Silicon Dioxide / Q000008:administration & dosage / Q000737:chemistry* / Q000378:metabolism; D014018:Tissue Distribution / Q000187:drug effects / Q000502:physiology
chemical_list: D012822:Silicon Dioxide